Non-antibiotic prevention of postcoital cystitis in women
DOI: 10.32364/2618-8430-2021-4-3-209-217
I.V. Kuz’min1, M.N. Slesarevskaya2, S.Kh. Al’-Shukri1
1I.P. Pavlov First St. Petersburg State Medical University, St. Petersburg, Russian Federation
2Research Institute for Surgery and Emergency Medicine of the I.P. Pavlov First Saint Petersburg
State Medical University, St. Petersburg, Russian Federation
Background: postcoital cystitis ranks first among recurrent infections of the lower urinary tract in young women. Their prevention is an important medical social issue. Prescription of antimicrobials for these infections increases antibacterial resistance of urinary tract pathogens, thereby requiring the search for alternative preventive strategies for postcoital cystitis.
Aim: to assess the effectiveness of diet correction using biologically active food supplement (BAFS) Ecocystin® containing D-mannose and inulin to prevent coitus-related infections of the lower urinary tract (postcoital cystitis) in women.
Patients and Methods: 40 sexually active women aged 18–45 (the mean age 31.9±8.8 years) with recurrent coitus-related infections of the lower urinary tract were enrolled. Women were divided into two groups, i.e., the study group (n=22) and the control group (n=18). Study group women received postcoital preventive treatment for the lower urinary tract infections (one sachet of BAFS Ecocystin® containing 1.5 g of mannose and 1.5 g of inulin no later than 2 hours after sexual intercourse and then another 12 hours later). Control group women received no preventive treatment. The primary indicator of the efficacy of postcoital prophylaxis was the rate of recurrent infections of the lower urinary tract. The additional indicator was the severity of clinical presentations assessed by the Acute Cystitis Symptom Score (ACSS) questionnaire. Follow-up was six months.
Results: the rate of recurrent infections of the lower urinary tract was significantly lower in the study group compared to the control group. Recurrences were reported in 27.3% in the study group and 77.8% in the control group over months 1–3 (χ2=10.01, p=0.002) and 13.6% and 72.2%, respectively, over months 4–6 (χ2=14.16, p<0.001). The chances for cystitis exacerbation during the first and the second trimester of the follow-up were 2.9- and 5.3-times lower in the study group compared to the control group. During the first trimester of the follow-up, the recurrence rate was 0.45±0.86 per one woman of the study group and 1.55±1.10 per one of the control group (t=3.6, p<0.001). During the second trimester of the follow-up, the recurrence rate was 0.18±0.50 and 1.50±1.20 (t=4.7, p<0.001), respectively. Women who received BAFS Ecocystin® but developed postcoital cystitis reported much lower symptom severity than the control group. As a result, the study group’s quality of life was significantly higher than the control group’s.
Conclusions: BAFS Ecocystin® is a highly effective and well-tolerated preventive tool for postcoital cystitis in women and a pathogenetically reasonable alternative for antibiotics.
Keywords: postcoital cystitis, infections of the lower urinary tract, recurrent cystitis, Ecocystin, D-mannose, inulin, non-antibiotic prophylaxis.
For citation: Kuz’min I.V., Slesarevskaya M.N., Al’-Shukri S.Kh. Non-antibiotic prevention of postcoital cystitis in women. Russian Journal of Woman and Child Health. 2021;4(3):209–217 (in Russ.). DOI: 10.32364/2618-8430-2021-4-3-209-217.
About the authors:
Igor V. Kuz’min — Dr. Sc. (Med.), professor of the Department of Urology, I.P. Pavlov First St. Petersburg State Medical University; 6–8, Lev Tolstoy str., St. Petersburg, 197022, Russian Federation; ORCID iD 0000-0002-7724-7832.
Margarita N. Slesarevskaya — C. Sc. (Med.), senior researcher of the Research Center of Urology, Research Institute for Surgery and Emergency Medicine of the I.P. Pavlov First Saint Petersburg State Medical University; 6–8, Lev Tolstoy str., St. Petersburg, 197022, Russian Federation; ORCID iD 0000-0002-4911-6018.
Salman H. Al-Shukri — Dr. Sc. (Med.), Professor, Head of the Department of Urology, I.P. Pavlov First St. Petersburg State Medical University; 6–8, Lev Tolstoy str., St. Petersburg, 197022, Russian Federation; ORCID iD 0000-0002-4857-0542.
Contact information: Igor V. Kuz’min, e-mail: kuzminigor@mail.ru.
Financial Disclosure: the study was conducted with the support of LLC ACINO RUS LLC. No authors have a financial or property interest in any material or method mentioned.
There is no conflict of interests.
Received 20.07.2021.
Revised 10.08.2021.
Accepted 27.08.2021.
2. Foxman B. Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk factors, and disease burden. Infect Dis Clin North Am. 2014;28(1):1–13. DOI: 10.1016/j.idc.2013.09.003.
3. Borisov V.V. Diagnosis and theraphy of urinary infections. What should always remember (clinical lecture). Part 1. Urologicheskie vedomosti. 2017;7(3):52–59 (Russ.). DOI: 10.17816/uroved7352-59.
4. Gupta K., Trautner B.W. Diagnosis and management of recurrent urinary tract infections in non-pregnant women. BMJ. 2013;346:f3140. DOI: 10.1136/bmj.f3140.
5. Perepanova T.S., Kozlov R.S., Rudnov V.A. et al. Antimicrobial therapy and prevention of infections of the kidneys, urinary tract and male genital organs. Federal clinical guidelines. M.; 2020 (in Russ.).
6. Bonkat G., Bartoletti R., Bruyere F. et al. EAU Guideline of Urological Infections. European Association of Urology; 2021 (Elecrtonic resource.) URL: http://uroweb.org/guideline/urological-infections. (access date: 06.04.2021).
7. Hooton T.M. Recurrent urinary tract infection in women. Int J Antimicrob Agents. 2001;17(4):259–268. DOI: 10.1016/s0924-8579(00)00350-2.
8. Scholes D., Hawn T.R., Roberts P.L. et al. Family history and risk of recurrent cystitis and pyelonephritis in women. J Urol. 2010;184(2):564–569. DOI: 10.1016/j.juro.2010.03.139.
9. Cai T. Recurrent uncomplicated urinary tract infections: definitions and risk factors. GMS Infect Dis. 2021;9:Doc03. DOI: 10.3205/id000072.
10. Al-Shukri S.H., Slesarevskaya M.N., Kuz’min I.V. Fosfomycin for treatment of uncomplicated lower urinary tract infection. Urologiia. 2018;(5):153–159 (in Russ.). DOI: 10.18565/urology.2018.5.153-158.
11. Kuzmin I.V., Al-Shukri S.Kh., Slesarevskaya M.N. Treatment and prophylaxis of the lower urinary tract recurrent infections in women. Urologicheskie vedomosti. 2019;9(2):5–10 (in Russ.). DOI: 10.17816/uroved925-10.
12. Slesarevskaya M.N., Kuz’min I.V., Al-Shukri S.H. Recurrent lower urinary tract infection in women: treatment and prevention. Urologiia. 2020;(6):64–69 (in Russ.). DOI: 10.18565/urology.2020.6.64-69.
13. Krasnyak S.S. Non-antibacterial therapy and prevention of acute and recurrent cystitis: existing options and future trends. Experimtntal and clinical urology. 2020;(1):136–143 (in Russ.). DOI: 10.29188/2222-8543-2020-12-1-136-143.
14. Ibishev Kh.S., Krakhotkin D.V., Mamedov E.A. et al. Importance of immunotherapy in the treatment of recurrent cystitis. Vestnik Urologii. 2021;9(1):87–94 (in Russ.). DOI: 10.21886/2308-6424-2021-9-1-87-9.
15. Loubet P., Ranfaing J., Dinh A. et al. Alternative Therapeutic Options to Antibiotics for the Treatment of Urinary Tract Infections. Front Microbiol. 2020;11:1509. DOI: 10.3389/fmicb.2020.01509.
16. Amdii R.E., Al-Shukri S.H., Kuzmin I.V. et al. Use of Kanefron in treatment of acute uncomplicated cystitis in women. Urology reports (St.-Petersburg). 2016;6(2):16–22 (in Russ.). DOI: 10.17816/uroved6216-22.
17. Slesarevskaya M.N., Kuz’min I.V., Al’-Shukri S.Kh. NefroCAPS phytolysin in complex management of women with chronic recurrent cystitis. Urologiia. 2018;(1):30–34 (in Russ.). DOI: 10.18565/urology.2018.1.30-34.
18. Kyriakides R., Jones P., Somani B.K. Role of D-Mannose in the Prevention of Recurrent Urinary Tract Infections: Evidence from a Systematic Review of the Literature. Eur Urol Focus. 2020:S2405–4569(20)30263–7. DOI: 10.1016/j.euf.2020.09.004.
19. Kuz’min I.V., Slesarevskaya M.N., Al-Shukri S.H. D-mannose for prevention and treatment of lower urinary tract infection: pathogenetic basics and clinical results. Urologiia. 2020;(4):131–138 (in Russ.). DOI: 10.18565/urology.2020.4.131-138.
20. Aronson M., Medalia O., Schori L. et al. Prevention of colonization of the urinary tract of mice with Escherichia coli by blocking of bacterial adherence with methyl alpha-D-mannopyranoside. J Infect Dis. 1979;139(3):329–332. DOI: 10.1093/infdis/139.3.329.
21. Kranjčec B., Papeš D., Altarac S. D-mannose powder for prophylaxis of recurrent urinary tract infections in women: a randomized clinical trial. World J Urol. 2014;32(1):79–84. DOI: 10.1007/s00345-013-1091-6.
22. Porru D., Parmigiani A., Tinelli C. et al. Oral D-mannose in recurrent urinary tract infections in women: a pilot study. J Clin Urol. 2014;7(3):208–213. DOI: 10.1177/2051415813518332.
23. Kuzmenko A.V., Kuzmenko V.V., Gyaurgiev T.A. Efficacy of combined antibacterial-prebiotic therapy in combination with D-mannose in women with uncomplicated lower urinary tract infection. Urologiia. 2019;(6):38–43 (in Russ.). DOI: 10.18565/urology.2019.6.38-43.
24. Kuz’min I.V., Slesarevskaya M.N., Al-Shukri S.H. Antiadhesive strategy for non-antibacterial prophylaxis of recurrent lower urinary tract infections. Urologiia. 2021;(3):5–12 (in Russ.). DOI: 10.18565/urology.2021.3.5-12.
25. Meštrović T., Matijašić M., Perić M. et al. The role of gut, vaginal, and urinary microbiome in urinary tract infections: from bench to bedside. Diagnostics (Basel). 2020;11(1):7. DOI: 10.3390/diagnostics11010007.
26. Serbaeva E.R., Yakupova A.B., Magasumova Yu.R. et al. Inulin: natural sources, features of metabolism in plants and practical application. Biomics. 2020;12(1):57–79 (in Russ.). DOI: 10.31301/2221-6197.bmcs.2020-5.
27. Stapleton A., Latham R.H., Johnson C., Stamm W.E. Postcoital antimicrobial prophylaxis for recurrent urinary tract infection. A randomized, double-blind, placebo-controlled trial. JAMA. 1990;264(6):703–706.
28. Alidjanov J.F., Abdufattaev U.A., Makhsudov S.A. et al. New self-reporting questionnaire to assess urinary tract infections and differential diagnosis: acute cystitis symptom score. Urol Int. 2014;92(2):230–236. DOI: 10.1159/000356177.
29. Medina M., Castillo-Pino E. An introduction to the epidemiology and burden of urinary tract infections. Ther Adv Urol. 2019;11:1756287219832172. DOI: 10.1177/1756287219832172.
30. Thänert R., Reske K.A., Hink T. et al. Comparative genomics of antibiotic-resistant uropathogens implicates three routes for recurrence of urinary tract infections. mBio. 2019;10(4):e01977–01919. DOI: 10.1128/mBio.01977-19.
31. Czaja C.A., Stamm W.E., Stapleton A.E. et al. Prospective cohort study of microbial and inflammatory events immediately preceding escherichia coli recurrent urinary tract infection in women. J Infect Dis. 2009;200(4):528–536. DOI: 200.528-36.10.1086/600385.
32. Ikäheimo R., Siitonen A., Heiskanen T. et al. Recurrence of urinary tract infection in a primary care setting: analysis of a 1-year follow-up of 179 women. Clin Infect Dis. 1996;22(1):91–99. DOI: 10.1093/clinids/22.1.91.
33. Anderson G.G., Palermo J.J., Schilling J.D. et al. Intracellular bacterial biofilm-like pods in urinary tract infections. Science. 2003;301(5629):105–107. DOI: 10.1126/science.1084550.
34. Rosen D.A., Hooton T.M., Stamm W.E. et al. Detection of intracellular bacterial communities in human urinary tract infection. PLoS Med. 2007;4(12):e329. DOI: 10.1371/journal.pmed.0040329.
35. Elliott T.S., Reed L., Slack R.C., Bishop M.C. Bacteriology and ultrastructure of the bladder in patients with urinary tract infections. J Infect. 1985;11(3):191–199. DOI: 10.1016/s0163-4453(85)92997-4.
36. Lenger S.M., Bradley M.S., Thomas D.A. et al. D-mannose vs other agents for recurrent urinary tract infection prevention in adult women: a systematic review and meta-analysis. Am J Obstet Gynecol. 2020;223(2):265.e1–265.e13. DOI: 10.1016/j.ajog.2020.05.048.
37. Sauer M.M., Jakob R.P., Luber T. et al. Binding of the bacterial adhesin fimh to its natural, multivalent high-mannose type glycan targets. J Am Chem Soc. 2019;141(2):936–944. DOI: 10.1021/jacs.8b10736.
38. Tsukanov A.Yu., Mirzakadiyev A.A. Precoital Prevention of Acute Cystitis Associated with Sexual Intercourse. Effektivnaya farmakoterapiya. 2020;16(20):6–10 (in Russ.). DOI: 10.33978/2307-3586-2020-16-20-6-10.
This work is licensed under a Creative Commons «Attribution» 4.0 License.
